Two year data for CATT study reinforce safety concerns for intravitreal bevacizumab

Source: BioSpace , PharmaTimes, Ophthalmology
Area: News
The full two year data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) which compared bevacizumab (AvastinT) and ranibizumab (LucentisT) intravitreal injections for neovascular age-related macular degeneration (AMD) have been reported. [The study design and one year data have been reported previously - see NELM abstract below.]   The following findings were noted:   . The proportion of patients with one or more systemic serious adverse events was significantly higher with bevacizumab than ranibizumab (234 [39.9%] vs. 190 [31.7%]; adjusted risk ratio, (Read more...)

Full Story →